Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL3801456 | 0.92 | POLB (0.31) | POLBGRM2 | |
| SCHEMBL4012635 | 0.88 | CA12 (0.31) | CA12CA1CA9 | |
| SCHEMBL7209074 | 0.83 | POLB (0.35) | POLBALDH1A1TSHRCA12CA1 | |
| SCHEMBL30983348 | 0.80 | GSK3A (0.33) | — | |
| SCHEMBL3132415 | 0.77 | CA12 (0.34) | POLBALDH1A1TSHRCA12CA1 | |
| SCHEMBL9285475 | 0.76 | POLB (0.32) | POLB | |
| SCHEMBL43721 | 0.76 | POLB (0.32) | POLB | |
| SCHEMBL7431766 | 0.74 | POLB (0.31) | POLB | |
| SCHEMBL3938392 | 0.74 | RIPK1 (0.34) | POLBCA12CA1CA9 | |
| SCHEMBL230240 | 0.73 | CA12 (0.33) | CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5401634-A | Stable biologically active fluorochemical emulsions | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-03-28 | — | — | US | claimed |
| US-11872313-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-01-16 | — | — | US | disclosed |
| CN-111225958-B | Conductive antifouling coating composition | 哈佛大学校长及研究员协会 | 2023-06-20 | — | — | CN | disclosed |
| US-11141379-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2021-10-12 | — | — | US | disclosed |
| US-20210077400-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-03-18 | — | — | US | disclosed |
| US-20190192436-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-06-27 | — | — | US | disclosed |
| US-10201500-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2019-02-12 | — | — | US | disclosed |
| EP-2558072-B1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | UNIV WASHINGTON (US) | 2018-09-26 | — | — | EP | disclosed |
| US-9974866-B2 | Protein-poly(2-oxazoline) conjugates for enhanced cellular delivery and transport across biological barriers | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2018-05-22 | — | — | US | disclosed |
| US-9498439-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2016-11-22 | — | — | US | disclosed |
| EP-1363538-A2 | ENHANCED ULTRASOUND DETECTION WITH TEMPERATURE DEPENDENT CONTRAST AGENTS | Barnes-Jewish Hospital (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2003075960-A1 | AVIDIN DIMERS EFFECTIVE IN INCREASING THE CONCENTRATION OF RADIOACTIVE BIOTIN IN PRETARGETED RADIOIMMUNOTHERAPY | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-09-18 | — | — | WO | disclosed |
| US-20030059912-A1 | Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof | BIOTECON GESELLSCHAFT FUR BIOTECHNOLOGISCHE ENTWICKLUNG UND CONSULTING MBH | 2003-03-27 | — | — | US | disclosed |
| WO-2002060524-A2 | ENHANCED ULTRASOUND DETECTION WITH TEMPERATURE DEPENDENT CONTRAST AGENTS | BARNES-JEWISH HOSPITAL (US) | 2002-08-08 | — | — | WO | disclosed |
| US-20020102216-A1 | Enhanced ultrasound detection with temperature-dependent contrast agents | KEREOS, INC. | 2002-08-01 | — | — | US | disclosed |
| US-5401634-A | Stable biologically active fluorochemical emulsions | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-03-28 | — | — | US | disclosed |
| EP-0634916-A1 | METHOD AND MEANS FOR PREVENTING SECONDARY CATARACT | Pharmacia & Upjohn Aktiebolag (SE) | 1995-01-25 | — | — | EP | disclosed |
| WO-1994016648-A1 | METHOD AND MEANS FOR PREVENTING SECONDARY CATARACT | PHARMACIA AB (SE) | 1994-08-04 | — | — | WO | disclosed |
| EP-0257758-B1 | STABLE BIOLOGICALLY ACTIVE FLUOROCHEMICAL EMULSIONS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1993-03-10 | — | — | EP | disclosed |
| EP-0257758-A2 | Stable biologically active fluorochemical emulsions | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1988-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192436-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | FAP, PNP, TYMP | POLB 2681/4885ALDH1A1 404/4885TSHR 3981/4885 |
| US-11141379-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | FAP, PNP, TYMP | POLB 2681/4885ALDH1A1 404/4885TSHR 3981/4885 |
| US-20210077400-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | FAP, PNP, TYMP | POLB 2681/4885ALDH1A1 404/4885TSHR 3981/4885 |
| US-10201500-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | FAP, PNP, TYMP | POLB 2681/4885ALDH1A1 404/4885TSHR 3981/4885 |
| US-11872313-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | FAP, PNP, TYMP | POLB 2681/4885ALDH1A1 404/4885TSHR 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.